Idera Pharmaceuticals

Aceragen is a Durham, North Carolina-based rare disease biopharmaceutical company focused on developing and commercializing innovative therapies for patients with debilitating conditions.

Following the merger with Idera Pharmaceuticals in 2022, Aceragen is dedicated to advancing its pipeline of novel treatments, particularly in the area of rare genetic diseases. We leverage a patient-centric approach, combining scientific expertise with a deep understanding of the challenges faced by patients and their families.

Aceragen’s core expertise lies in the development of targeted therapies, utilizing innovative technologies to address unmet medical needs. We are committed to improving the lives of patients and their families through the discovery and delivery of transformative medicines. Our team combines decades of experience in drug development, manufacturing, and commercialization, ensuring a robust pathway to market for our promising therapies. We operate with a strong focus on ethical practices and patient well-being.